{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:22:56Z","timestamp":1774084976807,"version":"3.50.1"},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuro-Oncology"],"published-print":{"date-parts":[[2001,1,1]]},"DOI":"10.1215\/15228517-3-1-46","type":"journal-article","created":{"date-parts":[[2005,12,5]],"date-time":"2005-12-05T21:28:37Z","timestamp":1133818117000},"page":"46-54","source":"Crossref","is-referenced-by-count":28,"title":["Importance of dose intensity in neurooncology clinical trials: Summary Report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium"],"prefix":"10.1093","volume":"3","author":[{"given":"N. D.","family":"Doolittle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","container-title":["Neuro-Oncology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2011,4,23]],"date-time":"2011-04-23T14:30:47Z","timestamp":1303569047000},"score":1,"resource":{"primary":{"URL":"http:\/\/neuro-oncology.dukejournals.org\/cgi\/doi\/10.1215\/15228517-3-1-46"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1,1]]},"references-count":0,"aliases":["10.1093\/neuonc\/3.1.46"],"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1,1]]}},"URL":"https:\/\/doi.org\/10.1215\/15228517-3-1-46","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,1,1]]}}}